readthroughSign in
Nov 10, 2026Trial update

Genmab's Phase 3 China DLBCL trial of epcoritamab posts results, listed active not recruiting

A China-based sub-study comparing epcoritamab to chemotherapy in relapsed/refractory DLBCL shows results posted and primary completion reached.

The week's single notable update for Genmab centers on a Phase 3 trial of its bispecific antibody epcoritamab in China.

  • Epcoritamab (EPKINLY, GEN3013), a CD3xCD20 bispecific antibody from Genmab with AbbVie as collaborator, is being tested against physician-selected chemotherapy in a Phase 3 sub-study for relapsed or refractory diffuse large B-cell lymphoma in China (sponsor Genmab, collaborator AbbVie).1 Patients in the trial are randomly assigned to either epcoritamab or a pre-specified standard chemotherapy regimen, either R-GemOx or bendamustine plus rituximab.1 The study, registered as NCT07226752 and tied to the master protocol GCT3013-05, enrolled 72 participants (actual).1 Its primary completion date was October 13, 2025 (actual), and results were first posted on November 10, 2026, with overall status listed as active, not recruiting.1 The trial's main measure is overall survival, assessed over a time frame of up to approximately 3 years.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.